|Targets||Platelet-activating factor receptor (PAF-R)|
|Description||ABT-491, an imidazopyridine derivative, has been found to be a PAF receptor antagonist that was once studied against allergic rhinitis.|
|Synonyms||ABT-491 free base; UNII-AYB44L739V; CHEMBL369225; ABT 491; 4-ethynyl-3-[3-fluoro-4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]benzoyl]-N,N-dimethylindole-1-carboxamide|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
PAF-AN-1 is a platelet activating factor receptor (PAF) antagonist.
This active molecular is a dihydropyridine Platelet-Activating Factor (PAF) antagonist under the development of Pfizer. In Sep 2015, treatment for Asthma in USA...
CMI-392 is a dual antagonist of 5-lipoxygenese (IC50= 100 nM) and platelet-activating factor (PAF) receptor (IC50= 10 nM).
ABT-491, an imidazopyridine derivative, has been found to be a PAF receptor antagonist that was once studied against allergic rhinitis.
Ginkgolide C, extracted from the Ginkgo biloba leaves, a traditional Chinese medicine, significantly increases the formation of cyclic adenosine monophosphate (...
MK-287 is platelet activating factor (PAF) inhibitor originated by Merck & Co. It can potently inhibit [3H]C18-PAF binding to human platelet, PMN (polymorphonuc...
Aglafoline, isolated from Aglaia elliptifolia Merr, is a selective PAF-induced platelet aggregation inhibitor. And studies have shown that because aglafoline bl...
ABT-491 Hydrochloride is a potent, selective and orally active platelet-activating factor receptor (PAF-R) antagonist (Ki = 0.6 nM in human platelets).